AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Scientists reported findings from the dose-escalation part of STIMULUS-AML1 treatment with sabatolimab+venetoclax+azacitidine to test whether it improved ND-AML patient outcomes in comparison to Phase Ib responses with Sabatolimab+hypomethylating agent treatment.